Cargando…
Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)
Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-1...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583635/ https://www.ncbi.nlm.nih.gov/pubmed/33195473 http://dx.doi.org/10.3389/fcvm.2020.585866 |
_version_ | 1783599431958921216 |
---|---|
author | Polverino, Francesca Stern, Debra A. Ruocco, Gaetano Balestro, Elisabetta Bassetti, Matteo Candelli, Marcello Cirillo, Bruno Contoli, Marco Corsico, Angelo D'Amico, Filippo D'Elia, Emilia Falco, Giuseppe Gasparini, Stefano Guerra, Stefano Harari, Sergio Kraft, Monica Mennella, Luigi Papi, Alberto Parrella, Roberto Pelosi, Paolo Poletti, Venerino Polverino, Mario Tana, Claudio Terribile, Roberta Woods, Jason C. Di Marco, Fabiano Martinez, Fernando D. |
author_facet | Polverino, Francesca Stern, Debra A. Ruocco, Gaetano Balestro, Elisabetta Bassetti, Matteo Candelli, Marcello Cirillo, Bruno Contoli, Marco Corsico, Angelo D'Amico, Filippo D'Elia, Emilia Falco, Giuseppe Gasparini, Stefano Guerra, Stefano Harari, Sergio Kraft, Monica Mennella, Luigi Papi, Alberto Parrella, Roberto Pelosi, Paolo Poletti, Venerino Polverino, Mario Tana, Claudio Terribile, Roberta Woods, Jason C. Di Marco, Fabiano Martinez, Fernando D. |
author_sort | Polverino, Francesca |
collection | PubMed |
description | Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-19. Whether hypertension medications may increase the risk for death in older COVID 19 inpatients at the highest risk for the disease is currently unknown. Methods: Data from 5,625 COVID-19 inpatients were manually extracted from medical charts from 61 hospitals across Italy. From the initial 5,625 patients, 3,179 were included in the study as they were either discharged or deceased at the time of the data analysis. Primary outcome was inpatient death or recovery. Mixed effects logistic regression models were adjusted for sex, age, and number of comorbidities, with a random effect for site. Results: A large proportion of participating inpatients were ≥65 years old (58%), male (68%), non-smokers (93%) with comorbidities (66%). Each additional comorbidity increased the risk of death by 35% [(adj)OR = 1.35 (1.2, 1.5) p < 0.001]. Use of ACE inhibitors, ARBs, beta-blockers or Ca-antagonists was not associated with significantly increased risk of death. There was a marginal negative association between ARB use and death, and a marginal positive association between diuretic use and death. Conclusions: This Italian nationwide observational study of COVID-19 inpatients, the majority of which ≥65 years old, indicates that there is a linear direct relationship between the number of comorbidities and the risk of death. Among CVDs, hypertension and pre-existing cardiomyopathy were significantly associated with risk of death. The use of hypertension medications reported to be safe in younger cohorts, do not contribute significantly to increased COVID-19 related deaths in an older population that suffered one of the highest death tolls worldwide. |
format | Online Article Text |
id | pubmed-7583635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75836352020-11-13 Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) Polverino, Francesca Stern, Debra A. Ruocco, Gaetano Balestro, Elisabetta Bassetti, Matteo Candelli, Marcello Cirillo, Bruno Contoli, Marco Corsico, Angelo D'Amico, Filippo D'Elia, Emilia Falco, Giuseppe Gasparini, Stefano Guerra, Stefano Harari, Sergio Kraft, Monica Mennella, Luigi Papi, Alberto Parrella, Roberto Pelosi, Paolo Poletti, Venerino Polverino, Mario Tana, Claudio Terribile, Roberta Woods, Jason C. Di Marco, Fabiano Martinez, Fernando D. Front Cardiovasc Med Cardiovascular Medicine Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-19. Whether hypertension medications may increase the risk for death in older COVID 19 inpatients at the highest risk for the disease is currently unknown. Methods: Data from 5,625 COVID-19 inpatients were manually extracted from medical charts from 61 hospitals across Italy. From the initial 5,625 patients, 3,179 were included in the study as they were either discharged or deceased at the time of the data analysis. Primary outcome was inpatient death or recovery. Mixed effects logistic regression models were adjusted for sex, age, and number of comorbidities, with a random effect for site. Results: A large proportion of participating inpatients were ≥65 years old (58%), male (68%), non-smokers (93%) with comorbidities (66%). Each additional comorbidity increased the risk of death by 35% [(adj)OR = 1.35 (1.2, 1.5) p < 0.001]. Use of ACE inhibitors, ARBs, beta-blockers or Ca-antagonists was not associated with significantly increased risk of death. There was a marginal negative association between ARB use and death, and a marginal positive association between diuretic use and death. Conclusions: This Italian nationwide observational study of COVID-19 inpatients, the majority of which ≥65 years old, indicates that there is a linear direct relationship between the number of comorbidities and the risk of death. Among CVDs, hypertension and pre-existing cardiomyopathy were significantly associated with risk of death. The use of hypertension medications reported to be safe in younger cohorts, do not contribute significantly to increased COVID-19 related deaths in an older population that suffered one of the highest death tolls worldwide. Frontiers Media S.A. 2020-10-09 /pmc/articles/PMC7583635/ /pubmed/33195473 http://dx.doi.org/10.3389/fcvm.2020.585866 Text en Copyright © 2020 Polverino, Stern, Ruocco, Balestro, Bassetti, Candelli, Cirillo, Contoli, Corsico, D'Amico, D'Elia, Falco, Gasparini, Guerra, Harari, Kraft, Mennella, Papi, Parrella, Pelosi, Poletti, Polverino, Tana, Terribile, Woods, Di Marco, Martinez and the ItaliCO study group. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Polverino, Francesca Stern, Debra A. Ruocco, Gaetano Balestro, Elisabetta Bassetti, Matteo Candelli, Marcello Cirillo, Bruno Contoli, Marco Corsico, Angelo D'Amico, Filippo D'Elia, Emilia Falco, Giuseppe Gasparini, Stefano Guerra, Stefano Harari, Sergio Kraft, Monica Mennella, Luigi Papi, Alberto Parrella, Roberto Pelosi, Paolo Poletti, Venerino Polverino, Mario Tana, Claudio Terribile, Roberta Woods, Jason C. Di Marco, Fabiano Martinez, Fernando D. Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) |
title | Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) |
title_full | Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) |
title_fullStr | Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) |
title_full_unstemmed | Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) |
title_short | Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) |
title_sort | comorbidities, cardiovascular therapies, and covid-19 mortality: a nationwide, italian observational study (italico) |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583635/ https://www.ncbi.nlm.nih.gov/pubmed/33195473 http://dx.doi.org/10.3389/fcvm.2020.585866 |
work_keys_str_mv | AT polverinofrancesca comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT sterndebraa comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT ruoccogaetano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT balestroelisabetta comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT bassettimatteo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT candellimarcello comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT cirillobruno comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT contolimarco comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT corsicoangelo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT damicofilippo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT deliaemilia comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT falcogiuseppe comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT gasparinistefano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT guerrastefano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT hararisergio comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT kraftmonica comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT mennellaluigi comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT papialberto comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT parrellaroberto comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT pelosipaolo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT polettivenerino comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT polverinomario comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT tanaclaudio comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT terribileroberta comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT woodsjasonc comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT dimarcofabiano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT martinezfernandod comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico AT comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico |